Oncor Inc. of Gaithersburg, Md., has exclusively licensed fromChildren's Hospital of Philadelphia DNA probes that can identifypeople with congenital heart malformations that are due to aninherited abnormality of chromosome 22. The hospital servesas a human genome center for chromosome 22.
Through the license, Oncor will begin to build a position incardiovascular genetic tests to assess risk of disease onset andof passing a trait on to offspring.
Oncor (NASDAQ:ONCR) makes tests to detect and manage cancerand other genetic diseases.
(c) 1997 American Health Consultants. All rights reserved.